THE MEDICAL NEWS |
Popis: from News-Medical.Net - Latest Medical News and Research from Around the World
|
||||||
Adolescent cannabis use disorder diagnoses rise after legalization7:44 New diagnoses of cannabis use disorder (CUD) among adolescents in Northern California began climbing after recreational cannabis was legalized in California in 2016, reversing a steady decline in the three years prior, according to a new study published in the journal Addiction. Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC7:12 In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the St… Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC7:12 An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC). A study of more than 21,000 adults found an unusual link between psilocybin and diet7:12 Using data from more than 21,800 adults in two UK birth cohorts, researchers found that lifetime psilocybin and LSD use was associated with stronger pro-environmental attitudes and a greater likelihood of following a vegetarian diet, with psilocybin showing the clearer dietary pattern. Mediation analyses suggested that environmental attitudes statistically accounted for the psilocybin-vegetariani… T-DXd significantly extends progression-free survival in HER2-mutant NSCLC6:40 First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASL… Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer6:40 New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). Air pollution linked to higher risks of glaucoma and cataract6:40 People who live in areas with higher levels of air pollution are more likely to develop glaucoma and cataract, according to a large study presented today (Monday) at the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). Your voice could add something aging blood tests and scans miss6:40 Researchers found that a standardized 30-second voice recording could predict chronological age with mean absolute errors of 3.95 years in females and 4.41 years in males. The resulting Voice Age measure also captured physiological information partly distinct from molecular, imaging, sleep, and lifestyle-based aging clocks, supporting its potential as a functional aging biomarker. Smartphone imaging accurately supports remote cataract referral decisions6:40 Researchers have found a high level of agreement between cataract referral decisions based on smartphone images reviewed remotely and those made by ophthalmologists examining patients in person at rural eye camps. Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC6:40 Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented a… |
Noviny
Sépie
Černé
Konzole
Modré
Přihlásit
Založit účet
Souhrn
Moje
Home
World
Sport
Economy
Technology
Culture
Life & Style
Other